Ramoplanin oral

Drug Profile

Ramoplanin oral

Alternative Names: A 16686; A 16686A; MDL 62198; NTI-851; Ramoplanin

Latest Information Update: 01 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Ology Bioservices
  • Class Antiacnes; Antibacterials; Depsipeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vancomycin-resistant enterococcal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium-difficile-infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 01 Feb 2018 Discontinued - Phase-II for Clostridium difficile infections in USA (PO) (Ology Bioservices communication, February 2018)
  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 25 Jun 2015 Phase-II development in Clostridium difficile infections is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top